Slide 1: Exchange filing cover letter for investor presentation
Date: 15.10.2026 To National Stock Exchange of India Limited ‘Exchange Plaza’, Bandra-Kurla Complex Bandra (East), Mumbai 400051 Scrip Symbol: ACCENTMIC ISIN: INE0Q5D01013 Sub : Investor presentation for the Half year ended on 30th September 2026 Pursuant to the requirements of Regulation 30 of the
Slide 2: Accent Microcell Limited Investor Presentation H1FY27
ACCENT MICROCELL LIMITED Unleashing Potential Through Expertly Crafted Excipients Investor Presentation - H1FY27
Slide 3: Accent at a Glance
ACCENT AT A GLANCE 2
Slide 4: Accent at a Glance
ACCENT AT A GLANCE Manufacturing facilities in Gujarat - Pirana (Ahmedabad) and Dahej SEZ operating; Unit III at Nayka, Kheda under commissioning Business established in 2001 as a Core portfolio: Microcrystalline partnership firm; incorporated as a Cellulose (MCC), SMCC, MCC company on 10 April 2012
Slide 5: H1FY27 in Numbers
H1FY27 IN NUMBERS Vision Mission REVENUE ₹17,483.09 EBITDA 25.11% Growth in Every Granule Our foundation for quality FROM 25.4% YoY 609 bps YoY Our vision is to become a with innovative excellence OPERATIONS leading player in the Our mission is to build excipients segment by lasting trust through ex
Slide 6: Why Accent: Nine Reasons
WHY ACCENT: NINE REASONS 01 02 03 04 05 Pure-Play Scaled Premiumisation High Entry Unit III Unlocks MCC Leadership Operations with Driving Realisations Barriers & Regulatory Higher-Value Products 22 MCC grades, presence Capacity Headroom Premium mix increased from Moat Phase 1 adds 2,800 MTPA across
Slide 7: Our Journey
OUR JOURNEY 2001 2010 2015 2022 Established as Installed metal Expanded globally Converted to a public limited a Partnership Firm detector at Dahej through strategic company (December 2022); plant agreements plans for two additional 2012 factories Incorporated as 2006 Added other Accent Microcell 20
Slide 8: Our Promoters
OUR PROMOTERS Mr. Vasant Vadilal Patel Mr. Nitin Jasvantbhai Patel Chairman Executive Director 21+ years of experience in dyes, pharmaceuticals 21+ years of experience in technical operations. and nutraceuticals industries. Focuses on plant project implementation, Expertise in product development, m
Slide 9: What Accent Microcell Does?
WHAT ACCENT MICROCELL DOES? 8
Slide 10: Core Business
CORE BUSINESS Accent Microcell Ltd. makes the ingredients that turn a medicine Typical Tablet Composition into a tablet. ACTIVE DRUG A tablet is mostly not medicine. The active drug is usually only part of its weight; the rest comprises inactive ingredients called excipients. OTHER INGREDIENTS Excip
Slide 11: From Wood Pulp to Performance-Engineered Excipients
SO FROM WOOD PULP TO PERFORMANCE-ENGINEERED EXCIPIENTS How Accent Microcell creates value across the MCC value chain 01 | Source 02 | Manufacture 03 | Upgrade 04 | Grade & Quality 05 | Sell & Serve High-Purity Wood Controlled MCC Performance-Engineered Specification-Driven Global Customer Base Pulp
Slide 12: Product Portfolio
PRODUCT PORTFOLIO Main product Premium Premium Premium MCC Silicified MCC (SMCC) MCC Spheres MCC with CMC The filler and binder that gives a tablet its bulk and holds it together. MCC blended with silica so it flows better Tiny round beads that are coated with A blend that keeps liquid medicines eve
Slide 13: Manufacturing Facilities
MANUFACTURING FACILITIES Established MCC Manufacturing Base with High Utilisation and a Specialty-Excipient Expansion Pipeline Unit I | Pirana, Ahmedabad Unit II | Dahej SEZ, Bharuch Unit III | Navagam, Kheda — 2,000 MTPA | 3,900 sq. m. 7,200 MTPA | 20,060 sq. m. Specialty Excipient Platform Establi
Slide 14: R&D & Product Innovation
R&D & PRODUCT INNOVATION Building differentiated excipient technologies through continuous product development A Dedicated Innovation Engine 8-Year R&D Journey | Wood Pulp to CCS Accent has an active R&D and technical A key outcome of this R&D programme is the development development function focuse
Slide 15: Certification Stack - A High Barrier to Entry
CERTIFICATION STACK - A HIGH BARRIER TO ENTRY Building regulatory credentials takes more than certifications—it requires years of process validation, audits and customer qualification The Certification Stack EXCiPACT / GMP FSSC 22000 / FDA / US-DMF HALAL/ KOSHER / Pharma-excipient specific ISO 9001
Slide 16: Industry Overview
INDUSTRY OVERVIEW MCC & PHARMACEUTICAL EXCIPIENTS 15
Slide 17: Indian Pharmaceutical Industry — Government and Industry-Body Data
INDIAN PHARMACEUTICAL INDUSTRY — GOVERNMENT AND INDUSTRY-BODY DATA ₹4,71,898 Cr US$31.11 Bn Indian pharmaceutical industry India pharmaceutical exports, FY26 turnover, FY25 9.5% CAGR since FY21 (about 2% growth over US$30.5 Bn in FY25) Source: Department of Pharmaceuticals, Annual Report 2025-26 Sou
Slide 18: Excipient and MCC Market
EXCIPIENT AND MCC MARKET Global MCC market, 2025 Global CCS market, 2023 Key Demand Drivers US$1.3–1.6 Bn US$1.2 Bn 01 6.2–7.8% CAGR through 2030–33, Expected to reach US$2.4 Bn by 2032 | depending on source 7.8% CAGR Oral Solid Dose Growth MCC is a standard binder and filler for direct compression,
Slide 19: H1FY27 Performance
LL O Zz < = co O Lu oO LL Ou ~S N > — <-
Slide 20: P&L Statement
P&L STATEMENT in ₹ Lakhs Particular H1FY27 H2FY26 HoH% H1FY26 YoY% FY26 Revenue from Operations 17,483.09 20,966.58 (16.61%) 13,936.70 25.45% 34,903.28 Other income 255.59 416.66 (38.66%) 260.01 (1.70%) 676.67 Total Income 17,738.68 21,383.24 (17.04%) 14,196.71 24.95% 35,579.95 Total Expenditure 13,
Slide 21: Financial Graphs
FINANCIAL GRAPHS (in ₹ Lakhs | YoY% REVENUE FROM OPERATIONS EBITDA 65.61% RATIOS 25.45% 17,483.09 4,389.59 13,936.70 2,650.51 EBITDA Margin 25.11% H1FY26 H1FY27 H1FY26 H1FY27 PAT 72.24% PAT MARGIN 484 bps Annualised ROCE 3,111.60 17.80% 28.5% 1,806.82 12.96% Annualised ROE 21.5% H1FY26 H1FY27 H1FY26
Slide 22: Balance Sheet, Cash Flow and Returns
BALANCE SHEET, CASH FLOW AND RETURNS Balance Sheet in ₹ Lakh Cash Flow in ₹ Lakh Particular 30 Sept 2026 31 Mar 2026 Particular H1FY27 H1FY26 Share Capital 2,398.90 2,398.90 Cash flow from operations 7,828.08 625.41 Reserves and Surplus 28,021.28 25,149.56 Operating cash flow ÷ Operating EBITDA 1.78
Slide 23: Unit III - Project Economics, Funding and Status
UNIT III - PROJECT ECONOMICS, FUNDING AND STATUS Moving up the value chain from conventional MCC into CCS, SSG and pulp-based CMC 3× higher realisation potential Phase-wise Plan Phase 1 Phase 2 Products CCS, SSG, pulp-based CMC MCC – spray & non-spray Capacity 2,800 MTPA planned; about 2,400 MT fung
Slide 24: Unit III — Project Economics, Funding and Status
UNIT III — PROJECT ECONOMICS, FUNDING AND STATUS Funding Customer Qualification IPO (December 2023): ₹78.40 Balance sheet evidence: Phase 1 revenue depends on customer approval of new products, Cr raised, ₹54.39 Cr Capital work-in-progress which is a multi-year process for excipients earmarked for t
Slide 25: Shareholding, Liquidity and Main-Board Eligibility
SHAREHOLDING, LIQUIDITY AND MAIN-BOARD ELIGIBILITY Shareholding Pattern — 31 March 2026 in ₹ Cr Liquidity Measure Value* 3.59% 0.58% Share price ₹694 of which Alternative of which Foreign Investment Funds (7) Portfolio Investors (2) Market capitalisation ₹1,664 Cr 52-week high / low ₹731.70 / ₹253.0
Slide 26: Events and Exhibition
EVENTS AND EXHIBITION 1. Participation at Pharmaconex 2026, Egypt 2. Participation at IPHEX India 2026 3. Participation at CPHI Milan 2026 (1-3 September) (7-9 September) (6-8 October) Participated in IPHEX India 2026, held at Bharat 62,000+ attendees and 2,900+ exhibiting companies, Brought togethe
Slide 27: Disclaimer
DISCLAIMER This presentation and the accompanying slides (the “Presentation”), which have been prepared by Accent Microcell Limited (the “Companyˮ), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any secur
Slide 28: Thank You
THANK YOU 314, Shangrilla Arcade, Shyamal Cross Abhishek Bhutra | Himanshu Jain Roads, Anand Nagar Road, Satellite, Ahmedabad – 380015 Gujarat – INDIA. +91 80006 85556 , +91 89051 81853 inv_rel@accentmicrocell.com ir@finportalin.com Request Meeting & Investor Kit